An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Purpose: This study aimed to investigate the effect of Semaglutide on skeletal muscle and its metabolomics. Methods: A total of 18 male C57BL/6 mice were randomly divided into normal control (NC) group, high-fat diet (HFD) group and HFD+Semaglutide group, and were given standard diet, HFD diet, HFD diet plus Semaglutide, respectively. The body weight, gastrocnemius weight, serum lipid, blood glucose and inflammatory index levels of mice in each group were observed and compared, and the morphological and structural changes of gastrocnemius were also analyzed. Meanwhile, gastrocnemius metabolite changes were analyzed by untargeted metabolomics. Results: After Semaglutide treatment, the food intake and body weight of mice were evidently decreased, while the relative gastrocnemius weight ratio were conversely increased. Meanwhile, the levels of TG, CHO, LDL, HDL, TNF-α, IL-6, IL-1β and HOMA-IR were all observed to decrease remarkably after Semaglutide intervention. Histological analysis showed that Semaglutide significantly improved the pathological changes of gastrocnemius, manifested as increased type I/type II muscle fiber ratio, total muscle fiber area, muscle fiber density, sarcomere length, mitochondrial number and mitochondrial area. Furthermore, metabolic changes of gastrocnemius after Semaglutide intervention were analyzed, and 141 kinds of differential metabolites were screened out, mainly embodied in lipids and organic acids, and enriched in 9 metabolic pathways including a variety of amino acids. Conclusion: Semaglutide can significantly reduce the body weight and the accumulation of intramuscular fat, promote muscle protein synthesis, increase the relative proportion of skeletal muscle, and improve muscle function of obese mice, possibly by altering the metabolism of muscle lipids and organic acids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Weight-loss therapies such as those using GLP-1 receptor agonists (RA) have shown to be beneficial for sarcopenic obesity, however the data are mainly produced in preclinical studies and proper specific parameters of sarcopenic obesity assessed before and after the introduction of GLP-1 RA are required (92).”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [92]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, it has shown therapeutic effects on sarcopenic obesity.5”
From Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The emerging evidence suggests that GLP‐1 RAs increase mitochondrial area, number and morphology (i.e., reduces swelling).”
From The Effects of Glucagon-Like Peptide-1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They reported the high fat diet reduced mitochondrial number and area determined by TEM, which was then reversed following semaglutide treatment together with improvements in morphology, that is, reductions in swelling [36].”
From The Effects of Glucagon-Like Peptide-1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, GLP-1 RAs have recently been shown to improve sarcopenic obesity in obese mice by influencing the skeletal muscle metabolism [140,141,142].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [140]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trends in Obesity Among Adults in the United States, 2005 to 2014
Flegal, K. M., Kruszon-Moran, D., Carroll, M. D., Fryar, C. D., & Ogden, C. L. (2016) · JAMA · doi:10.1001/jama.2016.6458 · Cited by 2,803
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
Kovesdy, C. P., Furth, S. L., Zoccali, C., & on behalf of the World Kidney Day Steering Committee (2017) · American Journal of Nephrology · doi:10.1159/000458467 · Cited by 2,217
Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
DeFronzo, R. A., & Tripathy, D. (2009) · Diabetes Care · doi:10.2337/dc09-s302 · Cited by 2,102 · cited 1×
“The LBM is mainly composed of skeletal muscle, and lower skeletal muscle mass can lead to poorer glycemic control because it is the main site of glucose processing.(13) Furthermore, the reduction in muscle mass is synergistically accompanied by the accumulation of fat mass in T2DM, leading to the socalled “SO”.”
BackgroundA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 1×
“These mechanisms of action support the clinical development of anti-degradative glucagon-like peptide-1 receptor agonists (GLP-1RA) for the obesity, which was associated with type 2 diabetes mellitus, non-alcoholic fatty liver disease, and cardiovascular disease.(10,11) Although there is evidence that GLP-1RA can redu…”
BackgroundGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 1×
“Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone that inhibits glucagon secretion and can lead to weight loss with prolonged use.(8,9) These mechanisms of action support the clinical development of anti-degradative glucagon-like peptide-1 receptor agonists (GLP-1RA) for the obesity, which was associat…”
BackgroundSkeletal muscle: A brief review of structure and function
Frontera, W. R., & Ochala, J. (2015) · Calcified Tissue International · doi:10.1007/s00223-014-9915-y · Cited by 1,758 · cited 1×
“Mitochondria are the main part of energy generation, and the number of mitochondria can directly affect muscle function.(30) Therefore, Semaglutide was inferred to improve muscle function.”
BackgroundObesity and Severe Obesity Forecasts Through 2030
Finkelstein, E. A., Khavjou, O. A., Thompson, H., Trogdon, J. G., Pan, L., Sherry, B., & Dietz, W. (2012) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2011.10.026 · Cited by 1,418 · cited 1×
“associated with increased risk of disability, frailty, cardiometabolic disease, loss of independence, impaired quality of life, and mortality, thereby placing a heavy burden on individuals, societies, and health-care systems.(5,6) The pathogenesis of”
BackgroundSarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382 · cited 2×
“and oxidative stress all lead to loss of muscle mass and increase of fat mass.(7) Therefore, an in-depth understanding of the underlying mechanism of SO has innumerable benefits for its accurate diagnosis and effective prevention and treatment.”
BackgroundSarcopenic obesity: A new category of obesity in the elderly
Zamboni, M., Mazzali, G., Fantin, F., Rossi, A., & Di Francesco, V. (2008) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2007.10.002 · Cited by 953 · cited 1×
“In turn, muscle catabolism increased insulin resistance, thus resulting in fat mass gain.(28) Accumulating data suggested that GLP-1RAs have anti-inflammatory and insulin resistance-modifying effects.”
BackgroundSarcopenic Obesity Predicts Instrumental Activities of Daily Living Disability in the Elderly
Baumgartner, R. N., Wayne, S. J., Waters, D. L., Janssen, I., Gallagher, D., & Morley, J. E. (2004) · Obesity Research · doi:10.1038/oby.2004.250 · Cited by 937 · cited 1×
“Epidemiological data implied that SO was a better predictor of physical disability in older adults than sarcopenia or obesity alone.(25) Therefore, maintaining muscle mass during weight loss treatment is particularly important.”
Background
Cited by
Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management
Wei, S., Nguyen, T. T., Zhang, Y., Ryu, D., & Gariani, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1185221 · Cited by 291
“Weight-loss therapies such as those using GLP-1 receptor agonists (RA) have shown to be beneficial for sarcopenic obesity, however the data are mainly produced in preclinical studies and proper specific parameters of sarcopenic obesity assessed before and after the introduction of GLP-1 RA are required (92).”
BackgroundNevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
“In addition to weight loss, semaglutide has been shown to lower the intramuscular accumulation of fat and promote protidosynthesis in these mouse models, increasing both mass and muscle function [140].”
BackgroundStrategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity
Mechanick, J. I., Butsch, W. S., Christensen, S. M., Hamdy, O., Li, Z., Prado, C. M., & Heymsfield, S. B. (2025) · Obesity Reviews · doi:10.1111/obr.13841 · Cited by 149
Self-citationSarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease
Pοlyzos, S. A., Vachliotis, I. D., & Mantzoros, C. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155676 · Cited by 107
Spotlight on the Mechanism of Action of Semaglutide
Papakonstantinou, I. P., Tsioufis, K. P., & Katsi, V. K. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46120872 · Cited by 102
“Semaglutide demonstrated positive effects on body composition [47] with experimental evidence in obese mice showing body weight reduction and an optimal increase in muscle mass [160].”
Szekeres, Z., Nagy, A., Jahner, K., & Szabados, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158214 · Cited by 77
“TNF-α , IL-6, IL-1 β , and HOMA-IR were significantly lower in the semaglutide-treated group, suggesting that semaglutide has a beneficial effect on muscle function by reducing the inflammatory response and insulin resistance [51].”
BackgroundInfluentialAlissou, M., Demangeat, T., Folope, V., Van Elslande, H., Lelandais, H., Blanchemaison, J., Cailleaux, P., Guney, S., Aupetit, A., Aubourg, A., et al. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70141 · Cited by 72
“17 Xiang et al. also reported recently that Semaglutide protects skeletal muscle against obesity-induced muscle atrophy in obese HFD mice, via the SIRT1 pathway.”
Glucagon-like peptide-1 receptor agonists and muscle mass effects
Ceasovschih, A., Asaftei, A., Lupo, M. G., Kotlyarov, S., Bartušková, H., Balta, A., Sorodoc, V., Sorodoc, L., & Banach, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107927 · Cited by 64
Anti-inflammatory benefits of semaglutide: State of the art
Yaribeygi, H., Maleki, M., Jamialahmadi, T., & Sahebkar, A. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100340 · Cited by 72
The effects of GLP-1 agonists on musculoskeletal health and orthopedic care
Gatto, A., Liu, K., Milan, N., & Wong, S. (2025) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-025-09978-3 · Cited by 55
“In murine skeletal muscle, GLP-1R activation increased glycogen storage, increased glucose uptake, and enhanced mitochondrial biogenesis [57, 58].”
Old, V. J., Davies, M. J., Papamargaritis, D., Choudhary, P., & Watson, E. L. (2025) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13677 · Cited by 55
GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy
Lafferty, R. A., Flatt, P. R., & Irwin, N. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2192865 · Cited by 56
“muscle function in DIO mice [105], although translation to”
BackgroundRen, Q., Zhi, L., & Liu, H. (2025) · Drug Design, Development and Therapy · doi:10.2147/dddt.s531778 · Cited by 44
Self-citationHavranek, B., Loh, R., Torre, B., Redfield, R. L., & Halegoua-DeMarzio, D. L. (2025) · Scientific Reports · doi:10.1038/s41598-025-89408-z · Cited by 51
Nelson, L. W., Lee, M. H., Garrett, J. W., Pickhardt, S. G., Warner, J. D., Summers, R. M., & Pickhardt, P. J. (2024) · American Journal of Roentgenology · doi:10.2214/ajr.24.31805 · Cited by 35
Kakegawa, T., Sugimoto, K., Saito, K., Yunaiyama, D., Araki, Y., Wada, T., Takahashi, H., Yoshimasu, Y., Takeuchi, H., & Itoi, T. (2024) · Medicine · doi:10.1097/md.0000000000038444 · Cited by 32
“In an animal study, Ren et al [18] studied the effects of semaglutide on skeletal muscles and its metabolomics.”
MethodScheen, A. J. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101681 · Cited by 30
Effects of semaglutide on metabolism and gut microbiota in high-fat diet-induced obese mice
Sun, L., Shang, B., Lv, S., Liu, G., Wu, Q., & Geng, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1562896 · Cited by 41
Liu, T., Zhou, L., Chen, Y., Lin, J., & Zhu, H. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001896 · Cited by 22
GLP-1 receptor agonists in the context of cancer: the road ahead
Miousse, I. R. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00245.2025 · Cited by 23
“Animal studies support this hypothesis, showing lower levels of inflammation and improved muscle fiber ratio, area, and density in obese mice administered semaglutide (79).”
Novel Treatments for Obesity: Implications for Cancer Prevention and Treatment
Cuttica, C. M., Briata, I. M., & DeCensi, A. (2023) · Nutrients · doi:10.3390/nu15173737 · Cited by 18
“Semaglutide, on the other hand, appears to have positive effects on skeletal muscle; can significantly reduce body weight and intramuscular fat accumulation; promote muscle protein synthesis; increase the relative proportion of skeletal muscle and improve muscle function in obese mice by decreasing the levels of trigl…”
González-Luis, A., Llinares-Arvelo, V., Martínez‐Alberto, C. E., Hernández-Carballo, C., Fernández, C. M., Navarro‐González, J. F., & Donate‐Correa, J. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf223 · Cited by 23
Age Is Just a Number: Progress and Obstacles in the Discovery of New Candidate Drugs for Sarcopenia
Kim, H.-J., Jung, D., & Williams, D. R. (2023) · Cells · doi:10.3390/cells12222608 · Cited by 17
“Murine studies showed that semaglutide was effective in a male C57BL/6 mouse HFD model of sarcopenic obesity via modulation of the skeletal muscle metabolome to increase pathways related to amino acids instead of lipids and organic acids [110].”
Exploring the antioxidant properties of semaglutide: A comprehensive review
Yaribeygi, H., Maleki, M., Forouzanmehr, B., Kesharwani, P., Jamialahmadi, T., Karav, S., & Sahebkar, A. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108906 · Cited by 14
CORTES, T. M., Vásquez, L., Serra, M. C., Robbins, R. N., Stepanenko, A. R., Brown, K. R., Barrus, H., Campos, A., Espinoza, S. E., & Musi, N. (2024) · JMIR Research Protocols · doi:10.2196/62667 · Cited by 21
“…in obese mice resulted in an increase of type I/II muscle fibers, muscle fiber density, mitochondrial mass, and decline of TNF α , IL6, and IL-1 β compared to untreated obese mice, resulting in the semaglutide-treated mice having a muscle quality similar to the nonobese control group [42].”
BackgroundBarrea, L., Annunziata, G., Verde, L., Galasso, M., Savastano, S., Colao, A. A. L., & Muscogiuri, G. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00667-3 · Cited by 26
“…have shown a positive effect of semaglutide in promoting muscle protein synthesis, increasing the relative proportion of skeletal muscle, and improving muscle function [ 119 , 120], a synergistic dietary strategy such as the MD may help mitigate this concern and optimise the quality of weight loss.”
Targeting Sarcopenia in CKD: The Emerging Role of GLP-1 Receptor Agonists
Llinares-Arvelo, V., Martínez‐Alberto, C. E., González-Luis, A., Macía-Heras, M., Siverio-Morales, O., Navarro‐González, J. F., & Donate‐Correa, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168096 · Cited by 15
“Metabolomic profiling further indicates favorable shifts in amino acid, lipid, and organic acid pathways, suggesting enhanced anabolic signaling and metabolic efficiency [103], which may help to counteract uremic metabolic inflexibility.”
Wu, Y., Chen, Y., Corner, T. P., Nakashima, Y., Salah, E., Li, Z., Zhang, L., Yang, L., Tumber, A., Sun, Z., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202410438 · Cited by 15
Self-citationChen, W., Qin, H., Zhou, Z., Chen, Y., Xu, X., Chen, Y., He, J., Xu, R., Gao, H., & Lu, Q. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.10.006 · Cited by 17
How hypoxia affects microbiota metabolism in mice
Ailizire, A., Wang, X., Ma, Y., Yan, X., Li, S., Wu, Z., & Du, W. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1244519 · Cited by 10
“In a study of the effects of semaglutide on skeletal muscle and its metabolomics, it was found to significantly reduce body weight and intramuscular fat accumulation in obese mice, possibly by altering the metabolism of muscle lipids and organic acids (Ren et al., 2022).”
BackgroundWang, Y., Lan, B., Zhang, S., Mu, Y., Mi, J., Yu, J., Zhan, Q., Luo, B., Lin, F., Teng, J., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01877-4 · Cited by 8
“Through the inhibition of gastric emptying and reduction of food intake, GLP-1 receptor agonists can significantly suppress nutrient absorption, potentially leading to a decrease in muscle mass [54, 60].”
Chan, D., Lin, Y.-C., Tzeng, H.-P., Yang, R., Chiang, M., & Liu, S. (2024) · Tissue and Cell · doi:10.1016/j.tice.2024.102479 · Cited by 10
Subcutaneous adipose tissue and skeletal muscle mitochondria following weight loss
van der Kolk, B. W., Pirinen, E., Nicoll, R., Pietiläinen, K. H., & Heinonen, S. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.08.002 · Cited by 10
Danielak, A., & Magierowski, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107741 · Cited by 9
Wang, J., Wang, N., Guo, H., Niu, X., Hu, S., Pan, X., Wang, M., Zhang, D., Song, L., & Sun, B. (2025) · Biology of Reproduction · doi:10.1093/biolre/ioaf178 · Cited by 8
Self-citationImpact of Incretin-Based Therapy on Skeletal Muscle Health
Koceva, A., Janež, A., & Jensterle, M. (2025) · Medicina · doi:10.3390/medicina61091691 · Cited by 16
“In HFD-fed mice, semaglutide reduced systemic inflammation by lowering TNF α , IL-6, IL-1 β , and HOMA-IR [5].”
InfluentialSkeletal muscle growth to combat diabetes and obesity: the potential role of muscle‐secreted factors
Sammut, M. J., Thorne, B. R., & Melling, C. W. J. (2025) · Obesity · doi:10.1002/oby.24223 · Cited by 8
The impact of semaglutide use for weight loss on transforaminal lumbar interbody fusion outcomes
Khalid, S. I., Mirpuri, P., Massaad, E., Wang, R., Elsamadicy, A. A., Shin, J. H., & Adogwa, O. (2025) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2025.108952 · Cited by 11
“While GLP-1 agonists significantly reduce adiposity, thereby increasing the relative proportion of skeletal muscle, the precipitous shedding of weight has been shown to substantially decrease lean body mass by 25 – 33 % in humans [13,14].”
Han, Z., Gong, L., Xue, Y., Wang, R., Liu, J., Wang, X., Zhao, W., Liao, H., & Li, R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1426917 · Cited by 7
Bobu, A. M., Turliuc, Ș., Cucu, A. I., Onofriescu, A., Dascălu, C. G., Costea, C. F., Pătrășcanu, E., Morosan, A. P., Hăisan, A., Filip, C. N., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103536 · Cited by 7
Chen, L., Zheng, J., Ye, B., Huang, Y., & Wang, Z. (2025) · Experimental Gerontology · doi:10.1016/j.exger.2025.112874 · Cited by 7
Wilkinson, M., Rollin, T., Kuriakose, M., Haggerty-Goede, R. A. L., Miller, D. M., & Dunham‐Snary, K. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110370 · Cited by 6
Elvina, L., Chen, C., Nguyen, D. H. N., Wei, C.-C., Su, C., Fang, T., Sutanto, F., & Li, S. (2025) · Nutrients · doi:10.3390/nu17233656 · Cited by 10
“However, inadequate or poorly distributed protein intake blunts MPS and tilts the balance toward proteolysis, accompanied by reduced IGF-1/Akt/mTOR signaling, elevated proteolytic activity (MuRF-1 and Atrogin-1), and mitochondrial deterioration as observed in diabetic and obese muscle [28,43,71,73].”
Kwan, A. T. H., Lakhani, M., & McIntyre, R. S. (2026) · Clinical Nutrition · doi:10.1016/j.clnu.2026.106620 · Cited by 10
Yan, H., Yao, W., Li, Y., Li, T., Song, K., Yan, P., & Dang, Y. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s491970 · Cited by 6
“12 Previous metabolomics studies have confirmed the cardioprotective effects of semaglutide and changes in metabolic types in mice with heart failure induced by stress load.”
Wang, X., Wang, X., Zhuang, H., Lu, G., & Zhao, G. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178429 · Cited by 5
Ru, Q., Xu, C., Wan, C., Cheng, B., Xiang, X., Fang, L., Ren, J., Chen, L., & Wu, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031187 · Cited by 185
Diabetes Pharmacotherapy and its effects on the Skeletal Muscle Energy Metabolism
Yu, B., Wang, D., Zhou, J., Huang, R., Cai, T., Hu, Y., Zhou, Y., & Ma, J. (2024) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575299439240216081711 · Cited by 5
Barazzoni, R., Ballesteros-Pomar, M. D., Bischoff, S. C., Blaauw, R., Boirie, Y., Carey, S., Cederholm, T., Cortés, Y., Cuerda, C. G., Deutz, N. E. P., et al. (2026) · Clinical Nutrition · doi:10.1016/j.clnu.2026.106645 · Cited by 8
“In addition, preclinical studies have suggested that incretin-mimetic molecules employed for obesity management may have an independent muscle-anabolic impact [75], which might need to be directly evaluated in future studies.”
Wang, Y., Liu, J., Verbeke, K., Gasaly, N., Akkerman, R., & de Vos, P. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2026.100647 · Cited by 11
“In addition, in a model of sarcopenic obesity, semaglutide improved muscle quality by reducing intramuscular fat, enhancing mitochondrial density, and increasing type I muscle fiber area, thereby addressing concerns regarding potential adverse impacts on lean mass during weight loss [89].”
Liébana, L. R. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.2023.3.art3 · Cited by 5
Wang, S., Zhang, M., Yang, X., & Chen, S. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s498447 · Cited by 4
Self-citationImpaired Mitophagy Contributes to Pyroptosis in Sarcopenic Obesity Zebrafish Skeletal Muscle
Tang, X., Zou, Y., Yang, S., Chen, Z., Zhou, Z., Peng, X., & Tang, C. (2025) · Nutrients · doi:10.3390/nu17101711 · Cited by 6
Li, W., Cai, R., Yin, B., Zhou, Y., Dong, X., Li, W., & Wen, J. (2025) · Biology · doi:10.3390/biology14050575 · Cited by 4
“The weight loss may be attributed to changes in body fat mass. Consistent with previous studies, semaglutide-treated mice also showed reduced fat contents in various body regions, such as subcutaneous fat and peritesticular fat [25].”
Inhibition of Tumor Lipogenesis and Growth by Peptide‐Based Targeting of SREBP Activation
Luo, S., Huang, Y., Jiang, X., Wang, Z., He, X., Meng, Y., Li, S., Li, M., Xu, D., Mao, Z., et al. (2025) · Advanced Science · doi:10.1002/advs.202508111 · Cited by 8
Effects of antidiabetic agents on lipid metabolism of skeletal muscle: A narrative review
Xu, M., Lv, D., Wei, H., Li, Z., Jin, S., Liu, Q., Zhang, Y., & Liu, Y. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16189 · Cited by 5
“98 In addition, semaglutide was shown to significantly increase mitochondrial content and muscle function in HFD-induced mice.”
Self-citationSpry, E. R., Travis, K. B., Ragland, K. J., Klein, A. J., Zimmerman, J. M., & Vaughan, R. A. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2025.112629 · Cited by 3
The Impact of Liraglutide on Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease
So, J. E., Jeong, J., Hong, J. P., Kim, D. Y., Lee, J. S., Kim, M. N., Kim, B. K., Park, J. Y., Kim, D. Y., Lee, H. W., et al. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70134 · Cited by 3
“These data also align with mechanistic studies suggesting GLP-1 mediated preservation of muscle protein synthesis via modulation of mitochondrial function and inflammation [34, 35].”
Tao, Y., Wang, Z., Wang, Q., & Zhong, S. (2026) · Nutrition Reviews · doi:10.1093/nutrit/nuaf274 · Cited by 4
Wang, Q., Li, J., Yang, M., Guo, C., Zhang, M., Huang, C., Wang, X., Zhang, D., Zeng, L., Ke, H., et al. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70195 · Cited by 3
“For instance, the myostatin pro-peptide inhibits myostatin, showing potential in treating muscle-wasting diseases like cachexia and sarcopenia [16–18], while GLP-1, known for its role in glucose metabolism, may help address muscle wasting in obesity [19] and chronic kidney disease [20].”
Nadarajan, V., Panton, J. A., Vingan, N. R., Walmsley, C., Barillas, J., Lazzarini, A., Culver, A. J., Kenkel, J. M., & Akgul, Y. (2024) · Aesthetic Surgery Journal Open Forum · doi:10.1093/asjof/ojae127 · Cited by 3
Effects of Hypoglycemic Agents on The Musculoskeletal System: A Comprehensive Review
Zhao, J., Lv, S.-S., Qi, L., Cong, X., & Zhang, X. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s517101 · Cited by 5
“148 A similar study also demonstrated that liraglutide (400 μg/kg/d) and semaglutide (60 μg/kg/d) reduced weight gain, excess lipid accumulation, and muscle atrophy in HFD-fed mice, eliminated increases in muscle atrophy markers in skeletal muscle and C2C12 cells, and found that the protective…”
Diabetes and Sarcopenia: Metabolomic Signature of Pathogenic Pathways and Targeted Therapies
Danciu, A. A., Bala, C. G., Inceu, G., Vonica, C. L., Rusu, A., Román, G., & Ciobanu, D. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157574 · Cited by 4
“Semaglutide reduced gastrocnemius intramuscular fat accumulation, increased protein synthesis, and increased the proportion and the function of skeletal muscle in obese mice treated for 12 weeks and evaluated using untargeted metabolomics [76].”
4-week aerobic exercise training regulates systemic macrophage polarization in obese mice
Qin, J., 张, 海., Gao, X., Zhang, N., Zhang, X., & Ju, J.-S. (2026) · PeerJ · doi:10.7717/peerj.20604 · Cited by 3
Yang, Q., Wang, Y., Gao, G., Li, H., Gao, Y., & He, J. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02133-z · Cited by 2
“Semaglutide significantly downregulates the expression levels of key pro-inflammatory factors such as TNF-α, IL-6, and IL-1β in the gastrocnemius muscle, while effectively improving IR, as evidenced by a significant reduction in the Homeo-static Model Assessment of Insulin Resistance index [28].”
Yang, W., Hao, C., Wang, N., Xie, J., Zhou, B., Yang, Z., Zheng, A., Wei, J., Li, C., Xie, C., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2661854 · Cited by 3
“116,183,184 These effects are associated with activation of the Silent Information Regulator 2 homolog 1 (SIRT1) and YAP–TAZ pathways, suppression of UPS-mediated degradation, and inhibition of atrophy-related gene expression.”
Semaglutide reverses the chronic myopathy of hyperkalemic periodic paralysis: a case report
Brand, K., Landry, D. L., Mulhern, J. G., & Braden, G. L. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04068-5 · Cited by 2
“GLP-1s induce fast twitch (glycolytic and insulin resistant) to slow twitch (oxidative and insulin sensitive) fiber changes [18].”
InfluentialThe Interplay of Sarcopenic Obesity and Mental Health: A Complex Relationship
Cheah, L. J., & Cheah, K. J. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004582 · Cited by 3
Semaglutide: effects on eating behavior
Gorban, V. V., Arzumanyan, K., Kostyulina, M. Y., Mikhaylenko, D. A., Khvostikova, I. S., & Shkorkina, E. D. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-268 · Cited by 1
Macrophage CBX4 Potentiates Atherosclerosis by its SUMO E3 Ligase Activity
Zhao, Z., Xu, S., Ma, J.-Y., Zhang, Z., Liang, S., & Guo, J. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07724-y · Cited by 3
Zhang, G., Huang, L., & Liao, L. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1655263 · Cited by 1
Hong, D., Le, L., Chen, W., Long, W., & Fan, W. (2026) · EJNMMI Research · doi:10.1186/s13550-026-01373-4 · Cited by 2
Semaglutide targets muscle mitochondria to regulate glutamine metabolism and treat osteoarthritis
Tian, Y., Zheng, Z., Ma, Y., Ye, F., Pang, Y., Zhang, Z., Li, Z., Zhang, C., & Gao, J. (2026) · iScience · doi:10.1016/j.isci.2026.116347 · Cited by 1
“8,37 Therefore, to investigate the potential mitochondrial-related mechanisms underlying these processes, we constructed a developmental trajectory of MuSCs, myocytes, and mature myofibers using Monocle3 38 (Figure 4B).”
Self-citationNutrition clinique : ce qui a changé en 2022
Almeida, M. P., Fotsing, G., Gijs, E., & Barigou, M. (2023) · JMIG · doi:10.53738/revmed.2023.19.809-10.46 · Cited by 2
Yang, Y., Si, J., Mo, J., Li, J., Pan, B., Pan, Y., Jiang, L., Wang, D., & Feng, X. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1554537 · Cited by 3
Effect of Incretogenic Peptides on Non-Alcoholic Fatty Liver Disease
苏, 怡. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1361396
The effect of semaglutide on body weight in patients with type 2 diabetes mellitus
Demidova, T. Y., & Titova, V. V. (2024) · FOCUS Endocrinology · doi:10.15829/2713-0177-2024-5-1-04 · Cited by 3
Wu, Y., Chen, Y., Corner, T. P., Nakashima, Y., Salah, E., Li, Z., Zhang, L., Yang, L., Tumber, A., Sun, Z., et al. (2024) · Angewandte Chemie · doi:10.1002/ange.202410438
Self-citationDiacylglycerol kinase alpha regulates post-hepatectomy liver regeneration
Nakamoto, H., Shichi, S., Shirakawa, C., Suzuki, T., Kitamura, H., & Taketomi, A. (2025) · Scientific Reports · doi:10.1038/s41598-024-84403-2
“For further analysis of insulin resistance, homeostatic model assessment for insulin resistance (HOMA-IR) was performed 21 .”
Sarkopene Adipositas im Alter: Ursachen, Folgen und Behandlungsansätze
Rippl, M., Drey, M., & Schluessel, S. (2025) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2492-9415
“Um dem entgegenzuwirken, sollte vor sportli-chen Aktivitäten auf eine ausreichende Energiezufuhr geachtet und insbesondere der Protein-Anteil in der Nahrung erhöht werden [48, 49].”
SARKOPENINIS NUTUKIMAS: GYDYMO GALIMYBĖS
Kairytė, A. (2025) · Health Sciences · doi:10.35988/sm-hs.2025.196
Tomasiewicz, A., Zabierowski, J., Pachana, M., Kukuła, P., Piersiak, M., Sawczuk, H., Marschollek, J., & Ziomek, M. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.4067
Yang, R., Lin, Y.-C., Lan, K., Wang, C., Tzeng, H.-P., Chang, T.-Y., Chan, D., & Liu, S. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.119523
Sadiq, E., Liu, Y., Li, N., Zong, C., Li, X., Yu, T., Pu, Z., Alameri, L., Li, Z., Li, S., et al. (2026) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2026.112758
Self-citationZeng, J., Li, Y., Zhou, L., Gao, L., Huang, J., Tong, X., Zhao, Y., Lu, T., Fu, Z. L. Z. W. P. L. W. L. J., & Tan, L. (2026) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s572050
Woźniak, M., Tarcz, Z., Pyczek, G., Bogacka, J., Diniejko, A., Kuryłowicz, A., Mamcarz, A., & Śliż, D. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15176818 · Cited by 1
“While some studies suggest reductions in muscle mass during treatment, others report preservation or improvement of muscle-related parameters [9–11].”
Cautela, D., Valeria, I., Lombardi, A., Laratta, B., Castaldo, C. M., Balestrieri, M. L., Mocini, E., Migliaccio, S., & Tardito, D. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188057
“Two studies have identified the GLP-1R/AMPK axis as a key mechanism through which incretin signaling modulates mitochondrial function and metabolic remodeling in skeletal muscle [49,51].”
Skeletal Muscle Dysfunction in Heart Failure
Challa, A. A., Pandey, A., Brubaker, P. H., Kitzman, D. W., Bozkurt, B., & Kalra, D. K. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103353
Knapik, J., Fic, W., & Polak-Szczybyło, E. (2026) · Nutrients · doi:10.3390/nu18193247
“Both preclinical and clinical studies have demonstrated enhanced insulin sensitivity together with reductions in triglyceride concentrations, LDL cholesterol levels, and systemic inflammatory markers following GLP-1RA therapy [58,59,63,71,72].”
Liu, Z., Ren, X., Su, C., Wang, G., & Liu, J. (2026) · Healthcare · doi:10.3390/healthcare14193228 · Cited by 1
More than just adipose: the impact of GLP1RA on lean tissue
Julien, M., Jeromson, S., & Wright, D. C. (2026) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.90062.2026
Metadata
- Authors
- Ren, Q., Chen, S., Chen, X., Niu, S., Yue, L., Pan, X., Li, Z., & Chen, X.
- Affiliations
- Hebei Medical University (CN)
- First Hospital of Shijiazhuang (CN)
- Third Hospital of Hebei Medical University (CN)
- Corresponding author
- Chen, Shuchun
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2022-10
- Volume
- Volume 16
- Pages
- 3723-3735
- ISSN
- 1177-8881 (ISSN-L)
- PMC
- PMC9594960
- OpenAlex
- W4307377238
- Cited by
- 91
- References
- 41
- Citations by year
- 2026: 18 · 2025: 43 · 2024: 20 · 2023: 10
- FWCI
- 5.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Drug Design Development and Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, GLP-1 receptor agonists, sarcopenic obesity, skeletal muscle metabolism, gastrocnemius, high-fat diet, intramuscular fat, muscle fiber composition, mitochondrial density, muscle metabolomics, lipid metabolism, amino acid metabolism, insulin resistance, inflammation, muscle protein synthesis
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Semaglutide, Animals, Lipids, Male, Mice, Inbred C57BL, Mice, Obese, Obesity, Muscle, Skeletal, Mice, Sarcopenia, Diet, High-Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.